Home › Forums › Main Forum › Media & News › FDA approves elbasvir/grazoprevir (Zepatier) › FDA approves elbasvir/grazoprevir (Zepatier)
31 May 2016 at 3:07 am
#18074
To put that price in some perspective, Brazil is estimated to have 2 million people with HCV. Which means that treating all of them would cost $12.8 billion against an annual primary health care budget of $3.5 billion.
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND